ArticleFrontiers in pharmacology2025
Association analysis-based screening strategy for quality markers of Tengdan capsule in the treatment of hypertensive renal disease.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Network Pharmacology-Serum Metabolomics Integration Identifies Key Targets, Biomarkers and Mechanism of Sendeng-4 in Rheumatoid Arthritis Therapy.International journal of general medicine · 2026Article
- Developing and validating a clinlabomics-based machine-learning model for early detection of occult diabetic kidney disease: implications for primary care screening.Frontiers in endocrinology · 2026Article
- RPN1 at the crossroads of glycosylation, tumor immunity, and disulfidptosis.Frontiers in pharmacology · 2026Review
- 24-hour diastolic blood pressure average real variability predicts renal progression in diabetic kidney disease: a comprehensive cohort study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Hypertensive Renal Disease (HRD) is a chronic and progressive condition driven by sustained high blood pressure, which leads to renal fibrosis and, eventually, end-stage kidney failure. Tengdan Capsule (TDC), a traditional Chinese medicinal formulation, has shown therapeutic potential for managing HRD. However, the specific quality markers (Q-markers) responsible for its efficacy and the underlying molecular mechanisms remain insufficiently understood. This study aimed to identify candidate Q-markers of TDC and elucidate the molecular pathways through which it exerts its renoprotective effects, using an integrative association analysis-based approach. Methods: The chemical composition of TDC and its potential Q-markers were systematically characterized through Results: A total of 82 chemical constituents were identified in TDC, 51 detected Conclusion: This study presents a novel framework for Q-marker identification in traditional herbal formulations using association-based multi-omics integration. Salvianolic acid B and KLRD1 were key indicators of TDC's quality and efficacy. These findings offer new mechanistic insights into the action of TDC and support its standardized evaluation and therapeutic application in HRD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.